Bertrand William C JR
Known title: DirectorCIK: 0001291937
Associated companies
Transaction History
| ARDX | ▲ Buy | Grant | 12,345 | $0 | 6/16/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 26,455 | $0 | 6/16/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 19,390 | $0 | 6/18/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 41,551 | $0 | 6/18/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 11,023 | $0 | 6/14/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 16,581 | $0 | 6/15/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 118,613 | $0 | 6/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.